 |
 |
 |
|
The Impact of Antiretroviral Tablet Burden and
Polypharmacy on Viral Suppression in Treatment Naïve Patients
|
|
|
IDWeek 2016 Oct 26-30  
Anthony Mills1, Jennifer Fusco2, Kathy L. Schulman3, Cassidy Henegar2, Susan Zelt4, Ronald D'Amico4, and Felix Carpio5
1Southern California Men's Medical Group, Inc., Los Angeles CA ; 2Epividian, Inc., Durham, NC; 3Outcomes Research Solutions, Waltham, MA; 4Viiv Healthcare Inc., Research Triangle Park, NC; 5Altamed Health Services, Los Angeles, CA





|
|
|
 |
 |
|
|